• Biohaven licensed its Kv7 ion channel platform to SK Biopharmaceuticals under an exclusive worldwide agreement led by epilepsy candidate opakalim.
• Deal terms include up to USD 795 million in upfront and milestone payments tied to the Kv7 platform.
• Biohaven will receive USD 400 million in cash consideration, including USD 350 million at closing, USD 50 million in 2027.
• Additional economics include USD 150 million in development and regulatory milestones, tiered U.S. royalties from mid-teens to low twenties.
• Opakalim is in Phase 2/3 for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608260236PR_NEWS_USPR_____NE33068) on August 26, 2026, and is solely responsible for the information contained therein.